Literature DB >> 3196127

Hospital-acquired candidemia. The attributable mortality and excess length of stay.

S B Wey1, M Mori, M A Pfaller, R F Woolson, R P Wenzel.   

Abstract

Between 1977 and 1984, estimates of hospital-acquired bloodstream infections caused by Candida species increased in the United States from 0.5 to 1.5 per 10,000 admissions (National Nosocomial Infection Study data). We examined crude and attributable mortality rates and excess length of stay in 88 closely matched pairs of cases and controls with illnesses occurring between July 1983 and December 1986. The crude mortality rates for cases and controls were 57% and 19%, respectively; thus the attributable mortality rate was 38% with a 95% confidence interval of 26% to 49%. The risk ratio was 2.94 with a 95% confidence interval of 1.95 to 4.43. The median length of stay was 48 days for all cases and 40 days for all controls. An analysis of the length of stay for the 34 matched pairs that survived showed a median of 70 days for cases and 40 days for controls. Candida bloodstream infections represented 10% of all nosocomial bloodstream infections in the period studied at our University Hospital; they are associated with a significant medical and economic burden well above that expected of the underlying diseases alone.

Entities:  

Mesh:

Year:  1988        PMID: 3196127     DOI: 10.1001/archinte.148.12.2642

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  211 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Estimating attributable mortality of candidemia: clinical judgement vs matched cohort studies.

Authors:  S I Blot; K H Vandewoude
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

4.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

5.  Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion.

Authors:  B Beović; T Lejko-Zupanc; J Pretnar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

6.  Production, characterization, and epitope mapping of a monoclonal antibody against aspartic proteinase of Candida albicans.

Authors:  B K Na; G T Chung; C Y Song
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

7.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

8.  Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds.

Authors:  H Provine; S Hadley
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

9.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

10.  Candida albicans Amphotericin B-Tolerant Persister Formation is Closely Related to Surface Adhesion.

Authors:  Jing Sun; Zhigang Li; Haoyue Chu; Jing Guo; Guangshui Jiang; Qingguo Qi
Journal:  Mycopathologia       Date:  2015-09-18       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.